Robuta

https://www.biospace.com/alnylam-pharmaceuticals-initiates-phase-i-clinical-study-for-aln-ttrsc-a-subcutaneously-administered-rnai-therapeutic-targeting-transthyretin-ttr-f
alnylam pharmaceuticalsclinical studyinitiatesphase
https://www.gyretx.com/publications/preclinical-evaluation-of-a-next-generation-subcutaneously-administered-coagulation-factor-ix-variant-dalcinonacog-alfa/
next generationcoagulation factorpreclinicalevaluationsubcutaneously